Prospective Validation
Prospective validation completes the full validation program, including the Process Performance Qualification batches discussed in the related PPQ article, before any commercial product from the validated process is actually released for distribution, representing the standard, generally preferred approach for essentially all new products and processes given the comprehensive assurance it provides before any commercial product ever reaches patients. This approach genuinely front-loads validation effort and time before any commercial revenue can be realized from the process, a trade-off most companies and regulators consider well justified by the correspondingly stronger assurance prospective validation provides before patients are exposed to product from the new process.
Concurrent Validation
Concurrent validation instead releases individual batches for distribution as they are manufactured and pass their own release testing, while the overall validation program, including accumulating batch data, continues toward eventual completion, meaning early batches are released to market before the complete validation program has actually finished. This approach carries inherently greater risk than prospective validation, since it commits to releasing product before the full validation evidence base is complete, and is therefore reserved for specific, genuinely justified circumstances rather than adopted as a routine, convenient alternative to standard prospective validation.
When Concurrent Is Justified
Concurrent validation is generally justified only in specific circumstances, including genuine drug shortage situations where patient access needs create compelling justification for accepting the additional inherent risk, or for orphan drugs and other products where very limited batch production volume makes waiting for full prospective validation completion impractical relative to genuine patient need. Justification should be explicit, documented, and specific to the actual circumstances at hand, not a general business preference for faster time-to-market absent one of these genuinely compelling, patient-need-driven circumstances.
Documentation Expectations
Where concurrent validation is used, documentation must clearly justify why this elevated-risk approach is warranted for the specific situation, and the validation protocol should specify enhanced monitoring and more conservative release criteria for the early, concurrently released batches compared with what might be applied under standard, non-concurrent commercial release. This heightened rigor for concurrently released batches reflects the genuinely elevated risk being accepted by releasing product before the complete validation program has finished, warranting correspondingly heightened scrutiny of each individual batch released under this approach.
Regulatory Engagement for Concurrent Validation
Given concurrent validation's elevated inherent risk, proactive regulatory engagement is generally advisable before pursuing this approach, ensuring the relevant regulatory authority understands and, where required, formally concurs with the justification and enhanced controls being applied, rather than a company unilaterally deciding to pursue concurrent validation without any prior regulatory awareness or engagement regarding this elevated-risk approach.
Risk Mitigation During Concurrent Validation
Beyond enhanced individual batch release criteria, concurrent validation programs often incorporate additional risk mitigation measures, including more extensive in-process monitoring, faster and more rigorous investigation response for any deviation occurring during the concurrent period, and, in some cases, restricted initial distribution allowing product recall or further evaluation to remain more readily practical should a genuine concern emerge from later batches or ongoing validation data before the overall program formally completes.
Transitioning From Concurrent to Standard Commercial Operation
Once the overall validation program concurrently underway reaches successful completion, meeting the same acceptance criteria that would have applied under standard prospective validation, the process transitions to standard ongoing commercial production under normal Stage 3 continued process verification, with the concurrent validation period's enhanced monitoring and controls no longer necessary once this genuine, complete validation confidence has actually been established through the completed program.
Distinguishing Concurrent Validation From Retrospective Validation
Concurrent validation should not be confused with retrospective validation, an older approach relying entirely on historical production and testing data from a process already in long-standing routine use, which is now generally disfavored and rarely accepted by modern regulatory expectations given its inherent reliance on data not specifically generated under a validation-focused monitoring and control regime.
Leave your rating